Weighted Average Number of Shares Outstanding, Diluted of NovaBay Pharmaceuticals, Inc. from 30 Jun 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
NovaBay Pharmaceuticals, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 30 Jun 2010 to 30 Sep 2025.
  • NovaBay Pharmaceuticals, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Sep 2025 was 5,876,000, a 409% increase year-over-year.
  • NovaBay Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2020 was 35,076,000, a 62% increase from 2019.
  • NovaBay Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2019 was 21,641,000, a 27% increase from 2018.
  • NovaBay Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2018 was 17,058,000, a 11% increase from 2017.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

NovaBay Pharmaceuticals, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 5,876,000 +4,721,000 +409% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 5,818,000 +4,663,000 +404% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 5,415,000 +5,295,000 +4412% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q3 2024 1,155,000 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 1,155,000 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 120,000 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q3 2020 40,067,000 +16,854,000 +73% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2020 2020 Q3
Q4 2019 21,641,000 +4,583,000 +27% 01 Oct 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
Q3 2019 23,213,000 +6,065,000 +35% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 18,613,000 +1,321,000 +7.6% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2019 2019 Q2
Q1 2019 17,093,000 +423,000 +2.5% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2019 2019 Q1
Q4 2018 17,058,000 +1,734,000 +11% 01 Oct 2018 31 Dec 2018 10-K 25 Mar 2021 2020 FY
Q3 2018 17,148,000 +1,824,000 +12% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 17,292,000 +1,984,000 +13% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 16,670,000 +1,386,000 +9.1% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1
Q4 2017 15,324,000 +5,916,000 +63% 01 Oct 2017 31 Dec 2017 10-K 26 Mar 2020 2019 FY
Q3 2017 15,324,000 +4,411,000 +40% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 15,308,000 +7,901,000 +107% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 15,284,000 +11,198,000 +274% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 9,408,000 +6,624,000 +238% 01 Oct 2016 31 Dec 2016 10-K 29 Mar 2019 2018 FY
Q3 2016 10,913,000 -2,946,564,000 -100% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017 2017 Q3
Q2 2016 7,407,000 -2,645,819,000 -100% 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2
Q1 2016 4,086,000 +1,911,000 +88% 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017 2017 Q1
Q4 2015 2,784,000 +799,000 +40% 01 Oct 2015 31 Dec 2015 10-K 21 Mar 2018 2017 FY
Q3 2015 2,957,477,000 +2,906,656,000 +5719% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 2,653,226,000 +2,602,459,000 +5126% 01 Apr 2015 30 Jun 2015 10-Q 11 Aug 2016 2016 Q2
Q1 2015 2,175,000 -43,163,000 -95% 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016 2016 Q1
Q4 2014 1,985,000 +458,000 +30% 01 Oct 2014 31 Dec 2014 10-K 23 Mar 2017 2016 FY
Q3 2014 50,821,000 +13,354,000 +36% 01 Jul 2014 30 Sep 2014 10-Q 16 Nov 2015 2015 Q3
Q2 2014 50,767,000 +13,501,000 +36% 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2
Q1 2014 45,338,000 +8,582,000 +23% 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1
Q4 2013 1,527,000 -27,921,000 -95% 01 Oct 2013 31 Dec 2013 10-K 04 Mar 2016 2015 FY
Q3 2013 37,467,000 +8,183,000 +28% 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014 2014 Q3
Q2 2013 37,266,000 +8,595,000 +30% 01 Apr 2013 30 Jun 2013 10-Q 31 Jul 2014 2014 Q2
Q1 2013 36,756,000 +8,184,000 +29% 01 Jan 2013 31 Mar 2013 10-Q 01 May 2014 2014 Q1
Q4 2012 29,448,000 +3,675,000 +14% 01 Oct 2012 31 Dec 2012 10-K 26 Mar 2015 2014 FY
Q3 2012 29,284,000 +1,382,000 +5% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2013 Q3
Q2 2012 28,671,000 +5,191,000 +22% 01 Apr 2012 30 Jun 2012 10-Q 01 Aug 2013 2013 Q2
Q1 2012 28,572,000 +5,144,000 +22% 01 Jan 2012 31 Mar 2012 10-Q 02 May 2013 2013 Q1
Q4 2011 25,773,000 01 Oct 2011 31 Dec 2011 10-K 06 Mar 2014 2013 FY
Q3 2011 27,902,000 +4,567,000 +20% 01 Jul 2011 30 Sep 2011 10-Q 01 Nov 2012 2012 Q3
Q2 2011 23,480,000 +165,000 +0.71% 01 Apr 2011 30 Jun 2011 10-Q 09 Aug 2012 2012 Q2
Q1 2011 23,428,000 01 Jan 2011 31 Mar 2011 10-Q 03 May 2012 2012 Q1
Q3 2010 23,335,000 01 Jul 2010 30 Sep 2010 10-Q 07 Nov 2011 2011 Q3
Q2 2010 23,315,000 01 Apr 2010 30 Jun 2010 10-Q 10 Aug 2011 2011 Q2

NovaBay Pharmaceuticals, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2020 35,076,000 +13,435,000 +62% 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2021 2020 FY
2019 21,641,000 +4,583,000 +27% 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
2018 17,058,000 +1,734,000 +11% 01 Jan 2018 31 Dec 2018 10-K 25 Mar 2021 2020 FY
2017 15,324,000 +5,916,000 +63% 01 Jan 2017 31 Dec 2017 10-K 26 Mar 2020 2019 FY
2016 9,408,000 +6,624,000 +238% 01 Jan 2016 31 Dec 2016 10-K 29 Mar 2019 2018 FY
2015 2,784,000 +799,000 +40% 01 Jan 2015 31 Dec 2015 10-K 21 Mar 2018 2017 FY
2014 1,985,000 +458,000 +30% 01 Jan 2014 31 Dec 2014 10-K 23 Mar 2017 2016 FY
2013 1,527,000 -27,921,000 -95% 01 Jan 2013 31 Dec 2013 10-K 04 Mar 2016 2015 FY
2012 29,448,000 +3,675,000 +14% 01 Jan 2012 31 Dec 2012 10-K 26 Mar 2015 2014 FY
2011 25,773,000 +2,447,000 +10% 01 Jan 2011 31 Dec 2011 10-K 06 Mar 2014 2013 FY
2010 23,326,000 01 Jan 2010 31 Dec 2010 10-K 14 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.